Skip to main content

Table 1 Patient demographic and clinical characteristics

From: Role of biliary stent and neoadjuvant chemotherapy in the pancreatic tumor microbiome

Number of patients, n

27

Male sex, n (%)

18 (67)

Age (years)

63.9 ± 10.4

BMI (kg/m2)

28.8 ± 4.3

Tumor stage, n (%)

 IA

0

 IB

7 (26)

 IIA

5 (18)

 IIB

14 (52)

 III

1 (4)

 IV

0

Tumor Location, n (%)

 Head

18 (67)

 Body

3 (11)

 Tail

6 (22)

Preoperative biliary stent, n (%)

 No Stent

11 (41)

 Stent

16 (59)

 Stent type, n (%)

 

  Plastic

7 (26)

  Metal

7 (26)

  Unknown

2 (7)

Neoadjuvant chemotherapy, n (%)

 None

17 (63)

 Gemcitabine

7 (26)

 Gemcitabine/Paclitaxel

2 (7)

 Gemcitabine/Oxaliplatin

1 (4)

Recent antibiotic exposure (<  6 weeks preoperatively)

 Yes

3 (11)

 No

24 (89)

Operative procedure, n (%)

 Pancreaticoduodenectomy (Whipple)

18 (67)

 Distal pancreatectomy and splenectomy

9 (33)

Perioperative antibiotic prophylaxis, n (%)

 Cefazolin

12 (44)

 Cefoxitin

7 (26)

 Cefotetan

5 (18)

 Clindamycin

1 (4)

 Levofloxacin

1 (4)

 Unknown

1 (4)

Infectious postoperative complications, n (%)

 None

19 (70)

 Superficial SSI

3 (11)

 Deep/organ-space SSI

2 (7)

 Pancreatic anastomotic leak

5 (18)

Clostridium difficile colitis

2 (7)

 Urinary tract infection

2 (7)

 Parotiditis

1 (4)

Survival, n (%)

 Short-term survival (<  5 years)

17 (63)

 Long-term survival (>  5 years)

3 (11)

 Lost to follow up

7 (26)

  1. Continuous data presented as mean ± standard deviation. BMI Body mass index, SSI Surgical site infection